{'fraction_non_alphanumeric': 0.014230271668822769, 'fraction_numerical': 0.00258732212160414, 'mean_word_length': 5.7894736842105265, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Polycystic Ovary Syndrome and the Climacteric: Metabolic Consequences and Management

Polycystic ovary syndrome affects 20% of women of reproductive age. The increasing awareness of the metabolic abnormalities associated with the syndrome has lead to concern about the cardiovascular risk and its long-term health implications. Women with polycystic ovary syndrome are characterised by insulin resistance, central obesity and dyslipidemia which places them at a higher risk of developing diabetes and cardiovascular disease. Assessment of lipid profile and glucose tolerance should be considered. Since these women are at increased risk of endometrial carcinoma, assessment should be offered. The standard criteria for the prescription of hormone replacement therapy apply.